Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy

Journal of Clinical Investigation

Volumn 125, Issue 2, 2015, Pages 870-880

  Chandler, Randy J ^a   La Fave, Matthew C ^a   Varshney, Gaurav K ^a   Trivedi, Niraj S ^a   Carrillo Carrasco, Nuria ^b   Senac, Julien S ^a   Wu, Weiwei ^a   Hoffmann, Victoria ^c   Elkahloun, Abdel G ^a   Burgess, Shawn M ^a   Venditti, Charles P ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; PARVOVIRUS VECTOR; PLACENTA PROTEIN; RTL1 PROTEIN, MOUSE;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE LOCUS; GENE TARGETING; GENE THERAPY; GENETIC ANALYSIS; GENOTOXICITY; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROPOSON; VIRUS DNA CELL DNA INTERACTION; ANIMAL; CARCINOMA, HEPATOCELLULAR; DEPENDOPARVOVIRUS; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; LIVER NEOPLASMS; METABOLISM; MUTANT MOUSE STRAIN; PROCEDURES;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; LIVER NEOPLASMS; MICE; MICE, MUTANT STRAINS; PREGNANCY PROTEINS; TRANSDUCTION, GENETIC;

EID: 84922152390     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI79213     Document Type: Article

References (62)

1. Dismuke DJ, Tenenbaum L, Samulski RJ. Biosafety of recombinant adeno-associated virus vectors. Curr Gene Ther. 2013;13(6):434-452.
2. Asokan A, Schaffer DV, Samulski RJ. The AAV vector toolkit: poised at the clinical crossroads. Mol Ther. 2012;20(4):699-708.
3. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet. 2011;12(5):341-355.
4. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med. 2013;15(2):65-77.
5. Maguire AM, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. 2008;358(21):2240-2248.
6. Bainbridge JW, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med. 2008;358(21):2231-2239.
7. Nathwani AC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25):2357-2365.
8. Gaudet D, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 2013;20(4):361-369.
9. Yla-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther. 2012;20(10):1831-1832.
10. Donsante A, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science. 2007;317(5837):477.
11. Donsante A, et al. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther. 2001;8(17):1343-1346.
12. Bell P, et al. No evidence for tumorigenesis of AAV vectors in a large-scale study in mice. Mol Ther. 2005;12(2):299-306.
13. Li H, et al. Assessing the potential for AAV vector genotoxicity in a murine model. Blood. 2011;117(12):3311-3319.
14. Montini E. Quest for safety at AAValon. Blood. 2011;117(12):3249-3250.
15. Valdmanis PN, Lisowski L, Kay MA. rAAV-mediated tumorigenesis: still unresolved after an AAV assault. Mol Ther. 2012;20(11):2014-2017.
16. Rosas LE, Grieves JL, Zaraspe K, La Perle KM, Fu H, McCarty DM. Patterns of scAAV vector insertion associated with oncogenic events in a mouse model for genotoxicity. Mol Ther. 2012;20(11):2098-2110.
17. Bell P, et al. Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol Ther. 2006;14(1):34-44.
18. Koeberl DD. Vector-related tumorigenesis not found in ornithine transcarbamylase-deficient mice. Mol Ther. 2006;14(1):1-2.
19. Kay MA. AAV vectors and tumorigenicity. Nat Biotechnol. 2007;25(10):1111-1113.
20. Zhong L, et al. Recombinant adeno-associated virus integration sites in murine liver after ornithine transcarbamylase gene correction. Hum Gene Ther. 2013;24(5):520-525.
21. Gauttier V, et al. No tumour-initiating risk associated with scAAV transduction in newborn rat liver. Gene Ther. 2013;20(7):779-784.
22. Russell DW. AAV vectors, insertional mutagenesis, and cancer. Mol Ther. 2007;15(10):1740-1743.
23. Hatada I, Morita S, Obata Y, Sotomaru Y, Shimoda M, Kono T. Identification of a new imprinted gene, Rian, on mouse chromosome 12 by fluorescent differential display screening. J Biochem. 2001;130(2):187-190.
24. Luk JM, et al. DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival. J Biol Chem. 2011;286(35):30706-30713.
25. Chandler RJ, Venditti CP. Long-term rescue of a lethal murine model of methylmalonic acidemia using adeno-associated viral gene therapy. Mol Ther. 2010;18(1):11-16.
26. Carrillo-Carrasco N, Chandler RJ, Chandrasekaran S, Venditti CP. Liver-directed recombinant adeno-associated viral gene delivery rescues a lethal mouse model of methylmalonic acidemia and provides long-term phenotypic correction. Hum Gene Ther. 2010;21(9):1147-1154.
27. Senac JS, Chandler RJ, Sysol JR, Li L, Venditti CP. Gene therapy in a murine model of methylmalonic acidemia using rAAV9-mediated gene delivery. Gene Ther. 2012;19(4):385-391.
28. Chandler RJ, Venditti CP. Pre-clinical efficacy and dosing of an AAV8 vector expressing human methylmalonyl-CoA mutase in a murine model of methylmalonic acidemia (MMA). Mol Genet Metab. 2012;107(3):617-619.
29. La Fave MC, Varshney GK, Gildea DE, Wolfsberg TG, Baxevanis AD, Burgess S. MLV integration site selection is driven by strong enhancers and active promoters. Nucleic Acids Res. 2014;42(7):4257-4269.
30. Nakai H, Montini E, Fuess S, Storm TA, Grompe M, Kay MA. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet. 2003;34(3):297-302.
31. Riordan JD, et al. Identification of rtl1, a retrotransposonderived imprinted gene, as a novel driver of hepatocarcinogenesis. PLoS Genet. 2013;9(4):e1003441.
32. Wang PR, Xu M, Toffanin S, Li Y, Llovet JM, Russell DW. Induction of hepatocellular carcinoma by in vivo gene targeting. Proc Natl Acad Sci U S A. 2012;109(28):11264-11269.
33. Manno CS, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342-347.
34. Chandler RJ, et al. Mitochondrial dysfunction in mut methylmalonic acidemia. FASEB J. 2009;23(4):1252-1261.
35. Wilnai Y, Enns GM, Niemi AK, Higgins J, Vogel H. Abnormal hepatocellular mitochondria in methylmalonic acidemia. Ultrastruct Pathol. 2014;38(5):309-314.
36. Jeganathan K, Malureanu L, Baker DJ, Abraham SC, Van Deursen JM. Bub1 mediates cell death in response to chromosome missegregation and acts to suppress spontaneous tumorigenesis. J Cell Biol. 2007;179(2):255-267.
37. Mahler JF, Stokes W, Mann PC, Takaoka M, Maronpot RR. Spontaneous lesions in aging FVB/N mice. Toxicol Pathol. 1996;24(6):710-716.
38. Nakamura K, Kuramoto K, Shibasaki K, Shumiya S, Ohtsubo K. [Age-related incidence of spontaneous tumors in SPF C57BL/6 and BDF1 mice]. Jikken Dobutsu. 1992;41(3):279-285.
39. Huser D, Gogol-Doring A, Chen W, Heilbronn R. Adeno-associated virus type 2 wild-type and vector-mediated genomic integration profiles of human diploid fibroblasts analyzed by third-generation PacBio DNA sequencing. J Virol. 2014;88(19):11253-11263.
40. Li C, Yu S, Zhong X, Wu J, Li X. Transcriptome comparison between fetal and adult mouse livers: implications for circadian clock mechanisms. PLoS One. 2012;7(2):e31292.
41. Dupuy AJ, et al. A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. Cancer Res. 2009;69(20):8150-8156.
42. Ranzani M, et al. Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer. Nat Methods. 2013;10(2):155-161.
43. Themis M, et al. Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol Ther. 2005;12(4):763-771.
44. Nowrouzi A, et al. The fetal mouse is a sensitive genotoxicity model that exposes lentiviral-associated mutagenesis resulting in liver oncogenesis. Mol Ther. 2013;21(2):324-337.
45. Hacein-Bey-Abina S, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348(3):255-256.
46. Barzel A, et al. Promoterless gene targeting without nucleases ameliorates haemophilia B in mice [published online ahead of print October 29, 2014]. Nature. doi:10.1038/nature13864.
47. McCarty DM. Self-complementary AAV vectors; advances and applications. Mol Ther. 2008;16(10):1648-1656.
48. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A. 2002;99(18):11854-11859.
49. Chen YH, Claflin K, Geoghegan JC, Davidson BL. Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease. Mol Ther. 2012;20(7):1393-1399.
50. Bantel-Schaal U, Hub B, Kartenbeck J. Endocytosis of adeno-associated virus type 5 leads to accumulation of virus particles in the Golgi compartment. J Virol. 2002;76(5):2340-2349.
51. Thomas CE, Storm TA, Huang Z, Kay MA. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol. 2004;78(6):3110-3122.
52. Salganik M, Aydemir F, Nam HJ, McKenna R, Agbandje-McKenna M, Muzyczka N. Adenoassociated virus capsid proteins may play a role in transcription and second-strand synthesis of recombinant genomes. J Virol. 2014;88(2):1071-1079.
53. Chandler RJ, et al. Metabolic phenotype of methylmalonic acidemia in mice and humans: the role of skeletal muscle. BMC Med Genet. 2007;8:64.
54. Varshney GK, et al. A large-scale zebrafish gene knockout resource for the genome-wide study of gene function. Genome Res. 2013;23(4):727-735.
55. Barnett DW, Garrison EK, Quinlan AR, Stromberg MP, Marth GT. BamTools: a C++ API and toolkit for analyzing and managing BAM files. Bioinformatics. 2011;27(12):1691-1692.
56. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10(3):R25.
57. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 2011;17: (1).
58. Linden RM, Ward P, Giraud C, Winocour E, Berns KI. Site-specific integration by adenoassociated virus. Proc Natl Acad Sci U S A. 1996;93(21):11288-11294.
59. Flicek P, et al. Ensembl 2013. Nucleic Acids Res. 2013;41(Database issue):D48-D55.
60. Kinsella RJ, et al. Ensembl BioMarts: a hub for data retrieval across taxonomic space. Database (Oxford). 2011;2011:bar030.
61. Kent WJ. BLAT - the BLAST-like alignment tool. Genome Res. 2002;12(4):656-664.
62. Kent WJ, et al. The human genome browser at UCSC. Genome Res. 2002;12(6):996-1006.